High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$36.3M
$36,310,124
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Other
|
2026-03-31 | $1,342,857Largex2 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $9,492,596Whalex8 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
Other
|
2026-03-31 | $5,056 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Soteropoulos Paula
• Director
10b5-1 Sell
2026-03-31
$47,986
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
10b5-1 Sell
|
2026-03-31 | $47,986 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
Other
|
2026-03-24 | $232,893 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Soteropoulos Paula
• Director
10b5-1 Sell
2026-03-24
$2,153,712Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Director
10b5-1 Sell
|
2026-03-24 | $2,153,712Large | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
Other
|
2026-03-16 | $499,975x2 | M | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
Other
2026-03-12
$893,259x3
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2026-03-12 | $893,259x3 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
CARR EDWARD
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -36.3%
2026-03-12
$3,559,495Largex5
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -36.3%
|
2026-03-12 | $3,559,495Largex5 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
Other
|
2026-03-12 | $823,551 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Garcia Marino
• CEO
10b5-1 SellΔOwn -18.2%
2026-03-12
$10,016,381MEGAx5
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CEO
10b5-1 SellΔOwn -18.2%
|
2026-03-12 | $10,016,381MEGAx5 | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2026-03-12
$614,166x4
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2026-03-12 | $614,166x4 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 Sell
2026-03-12
$2,756,468Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 Sell
|
2026-03-12 | $2,756,468Large | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Equity Compensation
|
2025-12-04 | $168,800x2 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2025-12-04 | $903,600 | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2025-11-14
$2,226,263Largex3
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2025-11-14 | $2,226,263Largex3 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 SellΔOwn -96.5%
2025-11-14
$4,158,442Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 SellΔOwn -96.5%
|
2025-11-14 | $4,158,442Large | S | Form 4 |
|
DNTH
M
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
Other
2025-11-13
$771,873x2
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
Other
|
2025-11-13 | $771,873x2 | M | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Randhawa Simrat
• Officer • EVP, Head of R&D
10b5-1 SellΔOwn -28.6%
2025-11-13
$3,221,445Largex3
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
Officer • EVP, Head of R&D
10b5-1 SellΔOwn -28.6%
|
2025-11-13 | $3,221,445Largex3 | S | Form 4 |